Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00504023 · OUTCOME

Percentage of Participants With Clinical and Histologic Remission

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva · Source last updated 2018-06-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
% of participants
Interval / dispersion
Not reported
Time frame
12 weeks post treatment

What was measured

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Groups in this outcome

Imiquimod

This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Imiquimod8

Reported measurements

Source class 1
Values in % of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imiquimod75Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        75
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
groups
  1. description
    This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
    id
    OG000
    title
    Imiquimod
param Type
NUMBER
reporting Status
POSTED
time Frame
12 weeks post treatment
title
Percentage of Participants With Clinical and Histologic Remission
type
PRIMARY
unit Of Measure
% of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice